BNB Plus Corp. FY product revenue rises 33 percent to USD 1.4 million
BNB Plus Corp. has reported its earnings for the full year ended September 30, 2025. The company recorded product revenues of USD 1.4 million for the period, representing a 33% increase. BNB Plus Corp. also disclosed that it raised USD 26.8 million in gross proceeds from a private placement of its common stock, pre-funded warrants, Series E-1 Warrants, and Series E-2 Warrants in October 2025. Additionally, the company received USD 0.7 million from exercised warrants during the same month. BNB Plus Corp. stated that it has sufficient cash, cash equivalents, and liquid cryptocurrency to fund its operations for at least the next twelve months. The company continues to focus on its BNB digital asset treasury strategy and the commercialization of proprietary nucleic acid production solutions through its LineaRx subsidiary.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BNB Plus Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-123342), on December 22, 2025, and is solely responsible for the information contained therein.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。